Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Myeloid Leukemia
- Sponsor
- University of Tennessee
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Oral anticancer agent adherence by proportion of days covered (PDC)
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The objective of this study is to improve medication, symptom, and disease management of patients with hematological malignancies and multiple chronic conditions (2 or more conditions in addition to cancer) through care coordination between pharmacists working in oncology practices and those working in primary care or community practices (Pharmacists Coordinated care Oncology Model [PCOM]).
This is a pilot study in which the investigators will examine the association between outcome measures, but the study design and sample size are insufficient to quantify the impact of OAA initiation or OAA adherence on adherence to chronic medications. This pilot study and data analyses are being done in preparation for a larger, controlled study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Receiving cancer care at Vanderbilt University Medical Center
- •Diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), chronic myeloid leukemia (CML), or multiple myeloma (MM)
- •Initiating an oral anticancer agent, either for the first time or a change from previous oral agent
- •Diagnosis of 2 chronic conditions, including at least one of the following: diabetes, hypertension, hyperlipidemia, congestive heart failure, depression/anxiety, gastroesophageal reflux disease, and/or chronic obstructive pulmonary disease
- •Patients taking at least two chronic medications, including at least one medication for one of the conditions listed above.
- •Willing and able to sign informed consent.
Exclusion Criteria
- •Cannot communicate in English
- •Concurrent diagnosis of type 1 diabetes or human immunodeficiency virus
Outcomes
Primary Outcomes
Oral anticancer agent adherence by proportion of days covered (PDC)
Time Frame: Up to 6 months post-initiation
PDC is a common medication adherence metric, and assesses the ratio of number of days the patient is supplied with oral anticancer agent, from the time of initiation until 6 months later, to the total number of days during that period. Data from the electronic medical record for dose changes will be aligned with the refill data to calculate a dose-adjusted PDC.
Chronic disease medication adherence
Time Frame: 6 months pre- and post-initiation of the oral anticancer agent
PDCs for medications for select chronic diseases will be calculated for the 6 months before and after oral anticancer agent initiation
Secondary Outcomes
- Oncology pharmacist review of patient-reported outcome measure(Approximately 44 days after oral anticancer agent initiation)
- Percent of Comprehensive Medication Reviews (CMRs) where note was routed to oncology pharmacist(Approximately 43 days after oral anticancer agent initiation)
- Patient-reported outcome measure completion(Approximately 42 days after oral anticancer agent initiation)
- Comprehensive Medication Review (CMR) completion(Approximately 50 days after oral anticancer agent initiation)
- Proportion of Comprehensive Medication Reviews (CMRs) reviewed by the oncology pharmacist(Approximately 44 days after oral anticancer agent initiation)